Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05078931 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 30, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Oct 2022 to Dec 30, 2025v4 Show 4 more changesShow less
    • Start date: Sep 23, 2021 to Oct 27, 2021
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: May 2024 to Dec 30, 2026
    • Site details revised
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 2021 to Sep 23, 2021
    • Site details revised
    v3
  3. Study sites: 0 to 1
    • Study description shortened, about 27 words
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will investigate the efficacy and safety of the combination of pembrolizumab and lenvatinib in PD-L1 positive patients with TKI-resistant EGFR-mutated advanced NSCLC.
Trial Details
NCT Number NCT05078931
Lead Sponsor Shanghai Chest Hospital
Collaborators: Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 NSCLC
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov